Stanford researchers in Dr. Mahajan's laboratory have discovered biomarkers to differentiate between infectious (endophthalmitis) and non-infectious uveitis; and, to accurately categorize the types of infectious uveitis.
Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.
Researchers at Stanford University have identified a small molecule tryptase inhibitor for treatment of severe allergies. Mast cells are a part of the innate and adaptive immune response. Mast Cell activation results in release of granules containing tryptases.
Stanford researchers have applied large-scale proteomic platforms to identify biomarkers that can be used to diagnose uveal melanoma and subtype eye tumors according to their gene expression profile (GEP) class or PRAME status.